Read by QxMD icon Read


Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu, Lizheng Shi
The original article can be found online.
May 16, 2019: PharmacoEconomics
Mark Bounthavong, Javed Butler, Chantal M Dolan, Jeffrey D Dunn, Kathryn A Fisher, Nina Oestreicher, Bertram Pitt, Paul J Hauptman, David L Veenstra
Correction to Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.
May 14, 2019: PharmacoEconomics
Stuart J Wright, William G Newman, Katherine Payne
BACKGROUND AND OBJECTIVE: Precision (stratified or personalised) medicine is underpinned by the premise that it is feasible to identify known heterogeneity using a specific test or algorithm in patient populations and to use this information to guide patient care to improve health and well-being. This study aimed to understand if, and how, previous economic evaluations of precision medicine had taken account of the impact of capacity constraints. METHODS: A meta-review was conducted of published systematic reviews of economic evaluations of precision medicine (test-treat interventions) and individual studies included in these reviews...
May 13, 2019: PharmacoEconomics
Mutsa Gumbie, Bonny Parkinson, Henry Cutler, Natalie Gauld, Virginia Mumford
BACKGROUND AND OBJECTIVE: Unplanned pregnancies can lead to poorer maternal and child health outcomes. The Australian Therapeutic Goods Administration committee rejected reclassifying a range of oral contraceptive pills (OCPs) from prescription to pharmacist-only medicines in 2015, mainly based on safety concerns. Improving access to OCPs may encourage some women to use contraceptives or switch from other contraceptive methods. However, some adverse events may increase and some women may stop using condoms, increasing their risk of sexually transmitted infections...
May 9, 2019: PharmacoEconomics
Joanna Emerson, Rachel Bacon, Alma Kent, Peter J Neumann, Joshua T Cohen
No abstract text is available yet for this article.
May 8, 2019: PharmacoEconomics
R Brett McQueen, Melanie D Whittington, Rick H Chapman, Varun M Kumar, Jonathan D Campbell
No abstract text is available yet for this article.
May 2, 2019: PharmacoEconomics
Marina Treskova, Stefan M Scholz, Alexander Kuhlmann
BACKGROUND: Previous systematic reviews concluded that pneumococcal vaccination in the elderly was cost effective. However, recently published economic evaluations state that it may not be cost effective when children are vaccinated with higher-valent pneumococcal conjugate vaccines. The literature suggests that the outcomes of vaccination in the elderly are strongly influenced by the vaccine effectiveness (VE) against the vaccine-type pneumococcal diseases (PD) and the impact of childhood vaccination on the vaccine-type PD incidence in the elderly, but the extent remains unclear...
April 26, 2019: PharmacoEconomics
Nikolaos Maniadakis, Evgenia Konstantakopoulou
BACKGROUND: Diabetic retinopathy (DR) affects approximately one-third of people diagnosed with diabetes, can be sight-threatening, and generates significant human and economic burden. Over the last 2 decades, newer therapies have emerged, offering significant clinical benefits, however at a cost. Given the scarcity of available budgets, the cost effectiveness of these newer treatments is of vital importance to policy makers. METHODS: A systematic review was conducted in the PubMed, EMBASE, Cochrane, HEED and CRD databases to find and evaluate economic evaluations assessing the cost effectiveness of alterative DR treatments...
April 22, 2019: PharmacoEconomics
Matthew Walton, Sahar Sharif, Mark Simmonds, Lindsay Claxton, Robert Hodgson
As part of the National Institute for Health and Care Excellence's (NICE's) Single Technology Appraisal (STA) process, Novartis submitted evidence on the clinical effectiveness and cost-effectiveness of tisagenlecleucel for treating paediatric and young adult patients (under the age of 25 years) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). This article presents a summary of the Evidence Review Group's (ERG's) independent review of the evidence submission, the committee's deliberations, and the subsequent development of NICE guidance for the use of tisagenlecleucel on the National Health Service (NHS) in England...
April 13, 2019: PharmacoEconomics
Kim Cocks, Marta Contente, Sarah Simpson, Michael DeRosa, Fiona C Taylor, James W Shaw
OBJECTIVES: In the CheckMate 141 trial (NCT02105636), nivolumab demonstrated survival, health-related quality of life, and healthcare resource utilization benefits vs single-agent therapy of investigator's choice (IC) (methotrexate, docetaxel or cetuximab) in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We assessed between-treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST)...
April 10, 2019: PharmacoEconomics
Scott D Grosse, Jamison Pike, Rieza Soelaeman, J Mick Tilford
Spillover effects on the welfare of family members may refer to caregiver health effects, informal care time costs, or both. This review focuses on methods that have been used to measure and value informal care time and makes suggestions for their appropriate use in cost-of-illness and cost-effectiveness analyses. It highlights the importance of methods to value informal care time that are independent of caregiver health effects in order to minimize double counting of spillover effects. Although the concept of including caregiver time costs in economic evaluations is not new, relatively few societal perspective cost-effectiveness analyses have included informal care, with the exception of dementia...
April 6, 2019: PharmacoEconomics
Simon Frey, Tom Stargardt, Udo Schneider, Jonas Schreyögg
BACKGROUND: Cystic fibrosis (CF) is a genetic disorder that is most common in white children and young adults. Long-term survival has improved steadily and will likely increase with the recent introduction of neonatal screening and causative treatment. However, these advances have substantial economic consequences for healthcare systems and payers. OBJECTIVE: This study aims to determine the economic burden of CF and to elucidate the structure of costs and the distribution of resources for different subpopulations, treatment strategies and sites of care for CF in Germany...
April 4, 2019: PharmacoEconomics
Steve Ryder, Kathleen Fox, Pratik Rane, Nigel Armstrong, Ching-Yun Wei, Sohan Deshpande, Lisa Stirk, Yi Qian, Jos Kleijnen
INTRODUCTION: There is a lack of comprehensive cost information for cardiovascular events since 2013. OBJECTIVE: A systematic review on the contemporary cost of cardiovascular events was therefore undertaken. METHODS: Methods complied with those recommended by the Cochrane Collaboration and the Centre for Reviews and Dissemination. Studies were unrestricted by language, were from 2013 to 23 December 2017, and included cost-of-illness data in adults with the following cardiovascular conditions: myocardial infarction (MI), stroke, transient ischaemic attack (TIA), heart failure (HF), unstable angina (UA), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or peripheral artery disease (PAD)...
April 4, 2019: PharmacoEconomics
Celia Sabry-Grant, Kinga Malottki, Alexander Diamantopoulos
BACKGROUND: The Cancer Drugs Fund (CDF) was established in 2010 to improve access to treatments not routinely available. Having widely overspent, stricter budgeting rules were introduced in 2016. The CDF can now only include treatments with potential to be cost effective once sufficient data are collected. OBJECTIVES: Our objective was to explore the process and criteria used for consideration of treatments under the new CDF framework and to describe the extent of evidence collection...
April 3, 2019: PharmacoEconomics
Lisa A Prosser, Eve Wittenberg
No abstract text is available yet for this article.
March 27, 2019: PharmacoEconomics
Pei-Jung Lin, Brittany D'Cruz, Ashley A Leech, Peter J Neumann, Myrlene Sanon Aigbogun, Dorothee Oberdhan, Tara A Lavelle
BACKGROUND AND OBJECTIVE: Alzheimer's disease or dementia can impose a significant burden on family and other informal caregivers. This study investigated how the inclusion of family/informal caregiver spillover effects in a cost-utility analysis may influence the reported value of Alzheimer's disease/dementia interventions. METHODS: We used PubMed to identify Alzheimer's disease or dementia cost-utility analyses published from 1 January, 2000 to 31 March, 2018...
March 22, 2019: PharmacoEconomics
Tara A Lavelle, Milton C Weinstein, Joseph P Newhouse, Kerim Munir, Karen A Kuhlthau, Lisa A Prosser
BACKGROUND: Few studies have used preference-based quality-of-life outcomes to assess how autism spectrum disorders (ASDs) affect children and parents, and none have examined variation by ASD severity. OBJECTIVE: Our objective was to derive parent valuations of child and parent health associated with varying ASD severity levels. METHODS: Parents of children aged 3-17 years with and without ASD were selected from a nationally representative research panel to complete a survey...
March 21, 2019: PharmacoEconomics
Sabine E Grimm, Debra Fayter, Bram L T Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen, Manuela A Joore
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda® ) to submit evidence of its clinical and cost effectiveness for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (RRcHL) who did not respond to treatment with brentuximab vedotin. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medical Centre+, was commissioned to act as the independent Evidence Review Group (ERG)...
March 21, 2019: PharmacoEconomics
Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer, Susan Griffin
The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Centre for Health Economics, both at the University of York, were commissioned as the independent evidence review group (ERG). The clinical-effectiveness data were from a multicentre randomised controlled trial that compared inotuzumab with standard of care (SoC), where SoC was the investigator's choice of chemotherapy...
March 19, 2019: PharmacoEconomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"